BEIJING, Aug. 11 /Xinhua-EMWNews/ -- Sinovac Biotech Ltd. (Amex:

SVA), a vaccine-focused biotech company in China, announced today that it

will hold its 2007 Annual Meeting of Shareholders on Thursday, September 4,

2008 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at

No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple

Street, St. John's, Antigua. All shareholders of record as of August 1,

2008 will be eligible to vote and are invited to attend.



    Sinovac Biotech Ltd.'s 2007 Annual Report, notice of annual general

meeting and proxy statement are available on the investors section of the

Company's website http://www.sinovac.com .

    About Sinovac



    Sinovac Biotech Ltd. is a China-based biopharmaceutical company that

focuses on the research, development, manufacture and commercialization of

vaccines that protect against human infectious diseases. Sinovac's

commercialized vaccines include Healive(R) (hepatitis A), Bilive(R)

(combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1).

Sinovac is currently developing Universal Pandemic Influenza vaccine and

Japanese encephalitis vaccine. Additional information about Sinovac is

available on its website, http://www.sinovac.com . To be added to our

distribution list, please email: [email protected].



    Safe Harbor Statement



    This announcement contains forward-looking statements. These statements

are made under the "safe harbor" provisions of the U.S. Private Securities

Litigation Reform Act of 1995. These forward-looking statements can be

identified by words or phrases such as "will," "expects," "anticipates,"

"future," "intends," "plans," "believes," "estimates" and similar

statements. Among other things, the business outlook and quotations from

management in this press release contain forward-looking statements.

Statements that are not historical facts, including statements about

Sinovac's beliefs and expectations, are forward-looking statements.

Forward-looking statements involve inherent risks and uncertainties. A

number of important factors could cause actual results to differ materially

from those contained in any forward-looking statement. Sinovac does not

undertake any obligation to update any forward-looking statement, except as

required under applicable law.






    For more information, please contact:



     Helen G. Yang

     Sinovac Biotech Ltd.

     Tel:   +86-10-8289-9871

     Fax:   +86-10-6296-6910

     Email: [email protected]



    Investors:

     Stephanie Carrington

     The Ruth Group

     Tel:   +1-646-536-7017

     Email: [email protected]



    Media:

     Janine McCargo

     The Ruth Group

     Tel:   +1-646-536-7033

     Email: [email protected]